The TreatmentTrends: Psoriasis 2015 (US) report explores treatment dynamics and their evolution among 100 U.S. dermatologists, through comprehensive primary research methods. The use of biologic products and Otezla prescribed for psoriasis is covered in particular detail. The report explores dermatologists’ awareness, trial, and usage of currently available brands, as well as familiarity with and interest in key emerging therapies.
Questions Answered in This Report:
- The use of biologic agents to treat moderate to severe psoriasis has been the mainstay for many years. Is there remaining opportunity for novel biologic agents in the psoriasis landscape?
- Brand share may be shifting away from the established tumor necrosis factor-alpha (TNF-alpha) inhibitors toward the more recently launched products. How do U.S. dermatologists anticipate market shares will evolve in the future?
- With several existing treatments, promotional messages to differentiate rival brands and to educate on how to use new brands become more important in physicians’ prescribing decisions. How are sales teams from the leading psoriasis brands interacting with dermatologists, and what messages are they delivering for key brands? Which sales representatives excel at conveying information about their respective brand?
- Psoriasis has an active pipeline with many novel treatments and alternative mechanisms of action, and the launches of the first biosimilar agents are on the horizon in the U.S. How will the availability of biosimilar agents and new psoriasis treatments affect dermatologists’ prescribing habits?
Markets covered: United States.
Primary research: Online survey of 100 U.S. dermatologists currently in clinical practice, spend more than 75% of their time in clinical practice, treating a minimum of 50 psoriasis patients and at least 25 psoriasis patients with a biologic agent.
Emerging therapies: Phase III: certolizumab pegol (Cimzia), guselkumab, ixekizumab, tildrakizumab, tofacitinib (Xeljanz).